Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $48.7 million.

  • Mereo BioPharma Group's Cash & Equivalents fell 39.52% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.7 million, marking a year-over-year decrease of 39.52%. This contributed to the annual value of $69.8 million for FY2024, which is 21.56% up from last year.
  • Latest data reveals that Mereo BioPharma Group reported Cash & Equivalents of $48.7 million as of Q3 2025, which was down 13.23% from $56.1 million recorded in Q2 2025.
  • Mereo BioPharma Group's 5-year Cash & Equivalents high stood at $153.9 million for Q2 2021, and its period low was $48.7 million during Q1 2024.
  • In the last 3 years, Mereo BioPharma Group's Cash & Equivalents had a median value of $60.0 million in 2023 and averaged $63.9 million.
  • Per our database at Business Quant, Mereo BioPharma Group's Cash & Equivalents soared by 310.18% in 2021 and then tumbled by 46.36% in 2022.
  • Over the past 5 years, Mereo BioPharma Group's Cash & Equivalents (Quarterly) stood at $127.1 million in 2021, then tumbled by 46.36% to $68.2 million in 2022, then fell by 15.78% to $57.4 million in 2023, then grew by 21.56% to $69.8 million in 2024, then tumbled by 39.52% to $48.7 million in 2025.
  • Its Cash & Equivalents stands at $48.7 million for Q3 2025, versus $56.1 million for Q2 2025 and $62.5 million for Q1 2025.